127 related articles for article (PubMed ID: 12988)
1. Pharmacology of a new phthalane (Lu 10-171), with specific 5-HT uptake inhibiting properties.
Christensen AV; Fjalland B; Pedersen V; Danneskiold-Samsoe P; Svendsen O
Eur J Pharmacol; 1977 Jan; 41(2):153-62. PubMed ID: 12988
[TBL] [Abstract][Full Text] [Related]
2. Neurochemical characterization of a new potent and selective serotonin uptake inhibitor: Lu 10-171.
Hyttel J
Psychopharmacology (Berl); 1977 Mar; 51(3):225-33. PubMed ID: 403537
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology in vivo of the phenylindan derivative, Lu 19-005, a new potent inhibitor of dopamine, noradrenaline and 5-hydroxytryptamine uptake in rat brain.
Arnt J; Christensen AV; Hyttel J
Naunyn Schmiedebergs Arch Pharmacol; 1985 Apr; 329(2):101-7. PubMed ID: 2409454
[TBL] [Abstract][Full Text] [Related]
4. Effect of a new series of bicyclic compounds with potential thymoleptic properties on the reserpine-resistant uptake mechanism of central and peripheral monoamine neurones in vivo and in vitro.
Carlsson A; Fuxe K; Hamberger B; Malmfors T
Br J Pharmacol; 1969 May; 36(1):18-28. PubMed ID: 5768100
[TBL] [Abstract][Full Text] [Related]
5. Neuroleptic influence on hyperthermia induced by 5-hydroxytryptophan and p-methoxy-amphetamine in MAOI-pretreated rabbits.
Fjalland B
Psychopharmacology (Berl); 1979 May; 63(2):113-7. PubMed ID: 38473
[TBL] [Abstract][Full Text] [Related]
6. Comparative studies of a new 5HT-uptake inhibitor and some tricyclic thymoleptics.
Lassen JB; Petersen E; Kjellberg B; Olsson SO
Eur J Pharmacol; 1975 May; 32(1):108-15. PubMed ID: 1149822
[TBL] [Abstract][Full Text] [Related]
7. Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor.
Claassen V; Davies JE; Hertting G; Placheta P
Br J Pharmacol; 1977 Aug; 60(4):505-16. PubMed ID: 302726
[TBL] [Abstract][Full Text] [Related]
8. Effect of a specific 5-HT uptake inhibitor, citalopram (Lu 10-171), on 3H-5-HT uptake in rat brain synaptosomes in vitro.
Hyttel J
Psychopharmacology (Berl); 1978 Dec; 60(1):13-8. PubMed ID: 104340
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology of lortalamine, a new potent non-tricyclic antidepressant.
Depin JC; Betbeder-Matibet A; Bonhomme Y; Muller AJ; Berthelon JJ
Arzneimittelforschung; 1985; 35(11):1655-62. PubMed ID: 4091869
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and pharmacological evaluation of the novel antidepressant and serotonin uptake inhibitor 2-(3,4-Dichlorobenzyl)-2-dimethylamino-1-propanol hydrochloride.
Gouret CJ; Porsolt R; Wettstein JG; Puech A; Soulard C; Pascaud X; Junien JL
Arzneimittelforschung; 1990 Jun; 40(6):633-40. PubMed ID: 2168703
[TBL] [Abstract][Full Text] [Related]
11. Effects of tandamine and pirandamine, new potential antidepressants, on the brain uptake of norepinephrine and 5-hydroxytryptamine and related activities.
Pugsley T; Lippmann W
Psychopharmacology (Berl); 1976 May; 47(1):33-41. PubMed ID: 1085452
[TBL] [Abstract][Full Text] [Related]
12. Sertraline, 1S,4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin.
Koe BK; Weissman A; Welch WM; Browne RG
J Pharmacol Exp Ther; 1983 Sep; 226(3):686-700. PubMed ID: 6310078
[TBL] [Abstract][Full Text] [Related]
13. The effects of 5-HT uptake- and MAO-inhibitors on L-5-HTP-induced excitation in rats.
Ortmann R; Waldmeier PC; Radeke E; Felner A; Delini-Stula A
Naunyn Schmiedebergs Arch Pharmacol; 1980 Mar; 311(2):185-92. PubMed ID: 6966764
[TBL] [Abstract][Full Text] [Related]
14. Du 24565, a quipazine derivative, a potent selective serotonin uptake inhibitor.
Vaatstra WJ; Deiman-Van Aalst WM; Eigeman L
Eur J Pharmacol; 1981 Mar; 70(2):195-202. PubMed ID: 6973481
[TBL] [Abstract][Full Text] [Related]
15. Investigations on the action and mechanism of action of diphenylhydantoin as an antagonist of tetrabenazine and reserpine.
Lotti VJ; Torchiana L; Porter CC
Arch Int Pharmacodyn Ther; 1973 May; 203(1):107-16. PubMed ID: 4125147
[No Abstract] [Full Text] [Related]
16. Antidepressant properties of 2-(4-ethyl-1-piperazinyl)-4-phenylquinoline hydrochloride (AD-1308) and its mechanism of action as compared with tricyclic antidepressants.
Karasawa T; Furukawa K; Ochi Y; Ito T; Yoshida K; Shimizu M
Arch Int Pharmacodyn Ther; 1980 Jun; 245(2):283-302. PubMed ID: 6773486
[No Abstract] [Full Text] [Related]
17. Behavioral effects and general pharmacology of 4-(5-chloro-benzofuranyl-2)-1-methylpiperidine HC1, an antidepressant inhibiting both monoamine oxidase A and 5-hydroxytryptamine uptake.
Ortmann R; Radeke E; Buech O; Sigg K; Rogg H; Glatt A; Truog A; Jaekel J; Everitt BJ; Delini-Stula A
Arzneimittelforschung; 1986 Dec; 36(12):1727-32. PubMed ID: 3566833
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the pharmacological and biochemical properties of substrate-selective monoamine oxidase inhibitors.
Christmas AJ; Coulson CJ; Maxwell DR; Riddell D
Br J Pharmacol; 1972 Jul; 45(3):490-503. PubMed ID: 5072232
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology of 1-(3,4-dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone, a novel antidepressant compound with antianxiety activity.
Ellis KO; Wessels FL; Burns RH; Pong SF
J Pharm Sci; 1980 Oct; 69(10):1198-1202. PubMed ID: 6106711
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology of 9-gamma-methylaminopropyl-9,10-dihydro-9,10-methanoanthracene-HCl (ID-9206-HCl), a new potent antidepressant.
Fukushima H; Nakamura M; Yamamoto H
Arch Int Pharmacodyn Ther; 1977 Sep; 229(1):163-76. PubMed ID: 931463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
